Literature DB >> 15516365

Hypoxic pulmonary hypertension is prevented in rats with common bile duct ligation.

Masatoshi Imamura1, Bao Luo, Jennifer Limbird, Andrea Vitello, Masahiko Oka, D Dunbar Ivy, Ivan F McMurtry, Chrystelle V Garat, Michael B Fallon, Ethan P Carter.   

Abstract

Biliary cirrhosis in the rat triggers intrapulmonary vasodilatation and gas-exchange abnormalities that characterize the hepatopulmonary syndrome. This vasodilatation correlates with increased levels of pulmonary microcirculatory endothelial NO synthase (eNOS) and hepatic and plasma endothelin-1 (ET-1). Importantly, during cirrhosis, the pulmonary vascular responses to acute hypoxia are blunted. The purpose of this work was to examine the pulmonary vascular responses and adaptations to the combination of liver cirrhosis and chronic hypoxia (CH). In addition to hemodynamic measurements, we investigated whether pulmonary expression changes of eNOS, ET-1 and its receptors (endothelin A and B), or heme oxygenase 1 in experimental cirrhosis affect the development of hypoxic pulmonary hypertension. We induced cirrhosis in male Sprague-Dawley rats using common bile duct ligation (CBDL) and exposed them to CH (inspired PO2 approximately 76 Torr) or maintained them in Denver (Den, inspired PO2 approximately 122 Torr) for 3 wk. Our data show 1) CBDL-CH rats had a persistent blunted hypoxic pulmonary vasoconstriction similar to CBDL-Den; 2) the development of hypoxic pulmonary hypertension was completely prevented in the CBDL-CH rats, as indicated by normal pulmonary arterial pressure and lack of right ventricular hypertrophy and pulmonary arteriole remodeling; and 3) selective increases in expression of ET-1, pulmonary endothelin B receptor, eNOS, and heme oxygenase 1 are potential mechanisms of protection against hypoxic pulmonary hypertension in the CBDL-CH rats. These data demonstrate that unique and undefined hepatic-pulmonary interactions occur during liver cirrhosis and chronic hypoxia. Understanding these interactions may provide important information for the prevention and treatment of pulmonary hypertension.

Entities:  

Mesh:

Year:  2004        PMID: 15516365     DOI: 10.1152/japplphysiol.00556.2004

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  5 in total

Review 1.  A brief overview of mouse models of pulmonary arterial hypertension: problems and prospects.

Authors:  Jose Gomez-Arroyo; Sheinei J Saleem; Shiro Mizuno; Aamer A Syed; Harm J Bogaard; Antonio Abbate; Laimute Taraseviciene-Stewart; Yon Sung; Donatas Kraskauskas; Daniela Farkas; Daniel H Conrad; Mark R Nicolls; Norbert F Voelkel
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-02-03       Impact factor: 5.464

2.  Morphological and biomechanical remodelling of the hepatic artery in a swine model of portal hypertension.

Authors:  Xi-Ju He; Ming-Hua Yu; Wen-Chun Li; Han-Qin Wang; Jing Li; Xing-Chun Peng; Jie Tang; Na Feng; Tie-Zhu Huang
Journal:  Hepatol Int       Date:  2011-09-23       Impact factor: 6.047

3.  Exogenous ghrelin improves blood flow distribution in pulmonary hypertension-assessed using synchrotron radiation microangiography.

Authors:  Daryl O Schwenke; Emily A Gray; James T Pearson; Takashi Sonobe; Hatsue Ishibashi-Ueda; Isabel Campillo; Kenji Kangawa; Keiji Umetani; Mikiyasu Shirai
Journal:  Pflugers Arch       Date:  2011-07-09       Impact factor: 3.657

4.  Development of occlusive neointimal lesions in distal pulmonary arteries of endothelin B receptor-deficient rats: a new model of severe pulmonary arterial hypertension.

Authors:  D Dunbar Ivy; Ivan F McMurtry; Kelley Colvin; Masatoshi Imamura; Masahiko Oka; Dong-Seok Lee; Sarah Gebb; Peter Lloyd Jones
Journal:  Circulation       Date:  2005-05-31       Impact factor: 29.690

5.  A central role for CD68(+) macrophages in hepatopulmonary syndrome. Reversal by macrophage depletion.

Authors:  Thenappan Thenappan; Ankush Goel; Glenn Marsboom; Yong-Hu Fang; Peter T Toth; Hannah J Zhang; Hidemi Kajimoto; Zhigang Hong; Jonathan Paul; Christian Wietholt; Jennifer Pogoriler; Lin Piao; Jalees Rehman; Stephen L Archer
Journal:  Am J Respir Crit Care Med       Date:  2010-12-10       Impact factor: 21.405

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.